Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™

Published: Tuesday, September 17, 2013
Last Updated: Tuesday, September 17, 2013
Bookmark and Share
67% survival demonstrated after 5 years and no transplant related mortalities.

Kiadis Pharma B.V. announced that the fiveyear follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR™ over a broad dose range. ATIR™ is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for patients who do not have a standard of care stem cell donor available. The results demonstrate proof of concept and show that ATIR™ infusion after a T-cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) provides immune protection shortly after the transplantation and improves long-term outcome in high-risk patients with very poor prognosis.

Not only does the study confirm that ATIR™ provides an effective treatment for patients for whom a standard of care stem cell donor is not available, the long term survival even seems to compare favorably to patients who do have a standard of care matched unrelated donor available. The overall survival of patients with high-risk malignancies in the Phase I/II study who received an efficacious dose of ATIR™ was 78% and 67% after one and five years, respectively. Data from the Center for International Blood & Marrow Transplant Research (CIMBTR) show that the one (and five) year survival of patients with acute myeloid leukemia (AML) who do have a standard of care matched unrelated donor available, varies from 65% (and 35%) in low-risk patients to 45% (and 20%) in high-risk patients, respectively.

In this Phase I/II study, 19 high-risk leukemia patients were treated with escalating doses of ATIR™ after a haploidentical HSCT. The five-year follow-up data show no transplant related mortality in the nine patients who received an efficacious dose of ATIR™. In addition, no Grade III-IV (life-threatening) acute Graft versus Host Disease (GvHD) was observed at any dose, which again compares favorably to standard of care matched unrelated donor transplantations, where (according to data from the CIBMTR) incidence of life-threatening GvHD is 30%. The strong five-year survival data also suggest that immune cells responsible for the Graft versus Leukemia effect are retained in ATIR™.

The results of the study allowed selecting the optimal ATIR™ dose for further development. Data from this five-year study will be published in due course in a peer-reviewed medical journal.
An international multi-center Phase II study including patients with AML, acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), to confirm and extend the data from the Phase I/II study, is now ongoing with topline results of the first phase expected in H1 2014.

Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: "The results from this study, which spans five years, show that ATIR™ might change the way in which patients with hematological malignancies will be treated. These data show that ATIR™ not only prevents significant infections without eliciting life-threatening GvHD, but also strongly improves survival rates in patients with high-risk malignancies and very poor prognosis. Our currently ongoing international Phase II clinical study is designed to confirm and extend these data to expedite moving ATIR™ towards regulatory approval."

Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and principal investigator for the study, added: "We are very excited about the long-term effects of ATIR™. In demonstrating very strong efficacy in minimizing posttransplantation risks and improving overall survival, these longterm data represent a potential major advancement in providing patients for whom a suitable matched donor is not available, with the opportunity to receive an HSCT from a mismatched family member with ATIR™ added as an adjunctive treatment."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Kiadis Pharma Receives Regulatory Approval from Health Canada
Company has received No Objection Letter for its new clinical study with ATIR™.
Thursday, February 28, 2013
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
ATIR™ is a cell-based product that enables stem cell transplantations from mismatched donors.
Monday, January 21, 2013
Kiadis Pharma Raises EUR 10 Million in Financing Round
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, has raised EUR 10 million in an equity financing round.
Tuesday, November 20, 2012
Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR(TM) in the United States.
Friday, July 09, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!